[BSD2000 deep hyperthermia combined with chemotherapy of PT regimen in patients with non-small cell lung cancer]

Zhongguo Fei Ai Za Zhi. 2010 Feb;13(2):132-5. doi: 10.3779/j.issn.1009-3419.2010.02.10.
[Article in Chinese]

Abstract

Background and objective: The aim of this study is to determine the short-term efficacy, toxicity and the rate of life-quality improvement of BSD2000 deep hyperthermia combined with chemotherapy of PT regimen in patients with non-small cell lung cancer (NSCLC) by comparation with PT regimen alone.

Methods: Sixty patients with NSCLC were randomly divided into the treatment group and control group, with 30 each. The treatment group was treated with chemotherapy (paclitaxel: 135 mg/m2 ivdirp 3 h qd d1+cisplatin: 20 mg/m2 ivdirp qd d1-5) in combination with BSD2000 deep hyperthermia, and hyperthermia was positioned precisely and maintained for 60 min (2 times a cycle: d1, 4 after the end of chemotherapy within two hours). The control group was treated with chemotherapy alone. Treatment response in both groups were evaluated as well as side-effects after 3 cycles. By observing the results, comparing response rate, toxic side effects and quality of life improvement rate in two groups.

Results: The efficiency and the rate of life-quality improvement in the treatment group were 63.33%, 76.67% respectively, and 36.67%, 40.00% in the control group respectively. There were significant differences between two groups (P < 0.05). The main side-effects were myelosuppression and gastrointestinal reactions, no significant difference between two groups (P > 0.05).

Conclusion: BSD2000 deep hyperthermia combined with chemotherapy in patients with NSCLC can significantly increase the efficacy, response rate and quality of life improvement and without increasing side-effects compared to chemotherapy alone.

背景与目的: 通过与PT方案单独化疗的对比观察, 探讨BSD2000深部热疗联合PT方案化疗治疗非小细胞肺癌(non-small cell lung cancer, NSCLC)的方法, 观察其近期疗效、毒副作用及生存质量改善率方面是否存在优势。

方法: 选择NSCLC患者60例, 随机分为治疗组和对照组, 各30例。治疗组:紫杉醇(paclitaxel, PTX)135 mg/m2 ivdirp 3 h qd d1+顺铂(cisplatin, DDP)20 mg/m2 ivdirp qd d1-5, 同时于d1、d4化疗结束后2 h内进行BSD2000热疗机精确定位热疗1 h, 21天为1周期, 共3周期。对照组:PTX 135 mg/m2 ivdirp 3 h qd d1+DDP 20 mg/m2 ivdirp qd d1-5, 21天为1周期, 共3周期, 不进行热疗。对比两组的有效率、毒副作用及生存质量改善率。

结果: 治疗组有效率、生存质量改善率分别为63.33%、76.67%, 对照组分别为36.67%、40.00%, 两组有效率及生存质量改善率有统计学差异(P < 0.05)。主要毒副作用均为骨髓抑制和消化道反应, 两组无统计学差异(P > 0.05)。

结论: BSD2000深部热疗联合PT方案化疗治疗d可明显提高疗效, 有效率及生存质量改善率优于单纯PT方案化疗, 毒副作用可耐受。

Publication types

  • English Abstract
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / therapy*
  • Female
  • Humans
  • Hyperthermia, Induced*
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / therapy*
  • Male
  • Paclitaxel / therapeutic use
  • Treatment Outcome

Substances

  • Paclitaxel